Cardiff Oncology (CRDF) EBITDA Margin Growth (1y) (2012 - 2026)
Cardiff Oncology (CRDF) EBITDA Margin Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 7,666.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1,238.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2,002.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3,558.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 29,091.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -1,651.00 |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - | 296,720.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 296,720.00 |
| Dec 31, 2025 | 510,484.00 |
| Sep 30, 2025 | -234,136.00 |
| Jun 30, 2025 | -451,608.00 |
| Mar 31, 2025 | -786,132.00 |
| Dec 31, 2024 | -170,275.00 |
| Sep 30, 2024 | 3,679.00 |
| Jun 30, 2024 | 360,738.00 |
| Mar 31, 2024 | 918,731.00 |
| Dec 31, 2023 | 71,442.00 |
| Sep 30, 2023 | 199,613.00 |
| Jun 30, 2023 | 17,212.00 |
| Mar 31, 2023 | 44,438.00 |
| Dec 31, 2022 | -17,509.00 |
| Sep 30, 2022 | -153,268.00 |
| Jun 30, 2022 | -134,494.00 |
| Mar 31, 2022 | -740,653.00 |
| Dec 31, 2021 | -170,274.00 |
| Sep 30, 2021 | -492,912.00 |
| Jun 30, 2021 | -59,135.00 |